Hot on the heels of its recent $2.3bn deal with Blackstone Group, Inc. for the sale of its Japanese consumer healthcare business, Takeda Pharmaceutical Company Limited. is continuing apace with non-core divestments, despite passing its strategic goal for such deals following the acquisition of Shire Pharmaceuticals Group PLC.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?